Search

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

ASRS: 2023

Biosimilars in the Real World

Carl C. Awh, MD, FASRS

Show Description +

Carl C. Awh, MD, FASRS, provides a look at the efficacy and safety of ranibizumab-nuna (Byooviz, Samsung Bioepis/Biogen) and ranibizumab-eqrn (Cimerli, Coherus) based on data from 16 retina practices.

Posted: 8/08/2023

Keywords:

retina-meeting-recap

•

biosimilars

•

ranibizumab-nuna

•

Ranibizumab

•

Byooviz

•

Samsung Bioepis

•

Biogen

•

ranibizumab-eqrn

•

Cimerli

•

Coherus

Up Next

An Update on Suprachoroidal RGX-314

An Update on Suprachoroidal RGX-314

David S. Boyer, MD

Treating GA With ANX007

Treating GA With ANX007

Jeffrey S. Heier, MD

Introducing a TWO-ROP Algorithm

Introducing a TWO-ROP Algorithm

Nimesh A. Patel, MD

When Infectious Retinitis Leads to an RD

When Infectious Retinitis Leads to an RD

Sruthi Arepalli, MD

ILM Flap Versus ILM Peeling for FTMH

ILM Flap Versus ILM Peeling for FTMH

Ankoor R. Shah, MD, FASRS

Wet AMD Incidence with GA Therapy

Wet AMD Incidence with GA Therapy

Roger Goldberg, MD, MBA

Tracking Vitreous Opacities After PPV

Tracking Vitreous Opacities After PPV

Shawn C. Kavoussi, MD

Methotrexate Shows Promise for Preventing PVR

Methotrexate Shows Promise for Preventing PVR

Christina J. Flaxel, MD

Codes for Concurrent GA and Wet AMD

Codes for Concurrent GA and Wet AMD

Jong G. Park, MD

High-Dose Aflibercept: 48-Week Data

High-Dose Aflibercept: 48-Week Data

Diana V. Do, MD, FASRS

Defining Anti-VEGF Response in CI-DME

Defining Anti-VEGF Response in CI-DME

Sharon D. Solomon, MD

Faricimab in Underrepresented Patients With DME

Faricimab in Underrepresented Patients With DME

Joseph M. Coney, MD, FASRS

A Closer Look at 8 mg Aflibercept

A Closer Look at 8 mg Aflibercept

David R. Chow, MD, FRCS(C)

Back to All Videos

Biosimilars in the Real World

Carl C. Awh, MD, FASRS

Carl C. Awh, MD, FASRS, provides a look at the efficacy and safety of ranibizumab-nuna (Byooviz, Samsung Bioepis/Biogen) and ranibizumab-eqrn (Cimerli, Coherus) based on data from 16 retina practices.

Posted: 8/08/2023

Keywords:

retina-meeting-recap

•

biosimilars

•

ranibizumab-nuna

•

Ranibizumab

•

Byooviz

•

Samsung Bioepis

•

Biogen

•

ranibizumab-eqrn

•

Cimerli

•

Coherus

Please log in to leave a comment.

More From ASRS: 2023 Coverage

When Infectious Retinitis Leads to an RD

When Infectious Retinitis Leads to an RD

Sruthi Arepalli, MD

ILM Flap Versus ILM Peeling for FTMH

ILM Flap Versus ILM Peeling for FTMH

Ankoor R. Shah, MD, FASRS

Wet AMD Incidence with GA Therapy

Wet AMD Incidence with GA Therapy

Roger Goldberg, MD, MBA

Tracking Vitreous Opacities After PPV

Tracking Vitreous Opacities After PPV

Shawn C. Kavoussi, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ASRS: 2023.